Engager des journalistes

Éditeurs et diffuseurs Équipes de marketing de contenu Équipes RP et communication Équipes risques et renseignement Trouver des journalistes Veille médias Tarifs

Pour les journalistes

Offres d'emploi en journalisme Tarifs Créez votre profil gratuit

À propos de Nicole

Avec 23 ans d'expérience en communication stratégique, Nicole a construit une carrière solide marquée par le dévouement et l'apprentissage continu. Nicole a commencé son parcours chez The Janssen Pharmaceutical Companies of Johnson & Johnson, où elle a passé la première décennie à perfectionner ses compétences en communication interne et externe, en image de marque d'entreprise, en stratégie de contenu et marketing, en communications par domaine thérapeutique, en relations publiques, en campagnes et en médias sociaux. Spécialisée en R&D Communications, Nicole a assumé des responsabilités belges, européennes, puis mondiales. Un projet majeur ‘From Molecule to Medicine’ placé sous sa direction a reçu trois prix prestigieux : la World Double Gold Medal at the New York Festivals et le Global Awards for the World's Best Work in Healthcare Communications. Cette réussite a mis en évidence la capacité de Nicole à diriger des initiatives à fort impact. Nicole a également développé des programmes visant à mobiliser et à former tant les employés internes que les parties prenantes externes, reflétant un engagement à favoriser une communication efficace au sein des organisations. Après dix ans, Nicole a fondé sa propre agence de communication, constituant un portefeuille diversifié de clients allant des startups aux multinationales. Bien que l'agence se soit principalement concentrée sur les secteurs de la santé et des sciences de la vie, elle a également servi des clients dans les domaines de l'IT, des RH et du conseil. L'expertise de l'agence en production de contenus créatifs et en campagnes a conduit à des projets réussis à travers la Belgique, l'Europe et les États-Unis. Depuis le début de la pandémie de COVID-19, Nicole travaille principalement en tant qu'experte indépendante en communication. Parallèlement à ses activités de communication en freelance, Nicole cultive une passion pour le journalisme en tant que correspondante santé freelance pour la Belgique chez Euractiv (Mediahuis). Ce rôle permet à Nicole de rester profondément connectée aux tendances actuelles du secteur de la santé, alliant son expertise en communication stratégique à un engagement pour des reportages informatifs et percutants jou

Langues
néerlandais anglais français allemand
Vu dans
Rapporteur Euractiv

Travaux 13

'Recipe to be dead-last': MEPs push to make biotech’s SPC reward count

Rapporteur 9 oct. 2026 English

MEPs backing the EU Biotech Act argue that an additional year of supplementary protection for a narrowly defined group of biotech medicines could encourage European research, manufacturing and patient access. Eligibility would require a new active substance, distinct and sufficiently safe and effective treatment, clinical trials in more than two EU member states, and at least one manufacturing step in the Union. Stine Bosse proposes early SPC candidate status linked to the European Medicines Agency’s PRIME scheme, a longer extension for orphan drugs and industry contributions to public-health infrastructure; Wouter Beke warns that overly strict conditions could undermine the incentive. Public payers and health technology assessment bodies warn of higher costs, while industry-backed modelling describes the budget impact as negligible. Committee votes are expected in December and a plenary vote around the turn of the year; trilogue negotiations are unlikely before 2027.

Biotechnology Pharmaceuticals Supplementary Protection Certificates European Union legislation Drug pricing and healthcare costs Clinical trials European Union Belgium Denmark European Parliament European Commission European Medicines Agency
Style rédactionnelInformatif

Mostly factual reporting, with attributed advocacy and competing arguments from MEPs and industry and public-payer stakeholders.

A Decade On, the Evidence Is In: What Biosimilar Treatment Means for Patients

Rapporteur 6 oct. 2026 English

A decade of biosimilar use in Europe has expanded access to biologic treatment for rheumatoid arthritis and related conditions, while evidence indicates patients switching to biosimilars generally maintain comparable effectiveness and safety. Studies report stable or improved outcomes, and regulators cite safety data covering one million patient-treatment years. Biosimilars have increased treatment use and generated substantial savings, but access remains markedly unequal: Eastern European patients receive far fewer treatment days with TNF-alpha inhibitors and biosimilars than patients elsewhere. Patient anxiety about switching remains important, making clear communication and reassurance essential.

Biosimilars Rheumatoid Arthritis Patient Access to Medicines Biologic Drugs European Healthcare Europe Eastern Europe United Kingdom European Medicines Agency World Health Organization National Rheumatoid Arthritis Society Newcastle Health Research Partnership
Style rédactionnelInformatif

Evidence-led reporting with a favorable framing of biosimilars and their impact on patient access.

Belgium needs cardiovascular plan by summer 2027, says cardiology head

Rapporteur 15 sept. 2026 English

Belgium should establish a national cardiovascular plan by summer 2027, according to cardiologist Rik Willems, who says an intergovernmental working group has begun discussions. The Belgian Society of Cardiology and Belgian Heart League propose embedding routine blood-pressure, cholesterol and blood-sugar checks in general practice, supported by a chosen risk score and electronic health records. Fragmented federal and regional responsibilities, limited disease and care-quality data, and misconceptions that cardiovascular disease affects only older people or results solely from personal choices are key barriers. Willems calls for political coordination, stronger data systems and teamwork across healthcare professions.

Cardiovascular Health Preventive Health Screening Belgian Health Policy Electronic Health Records Belgium European Union Belgian Society of Cardiology Belgian Heart League European Commission Belgian government European Society of Cardiology Rik Willems
Style rédactionnelInformatif

Primarily a factual interview, with some advocacy for coordinated prevention and improved cardiovascular care.

Contexte politiqueCentre

Focuses on public health coordination and policy implementation without advocating a partisan ideological position.

Only EU-based drugmaker in Trump's pricing deal keeps Europe guessing on cost

Rapporteur 11 sept. 2026 English

UCB, the only EU-headquartered company among nine drugmakers signing Donald Trump's most-favoured-nation pricing agreement, has pledged a more balanced approach to future medicine launches across developed markets, participation in a U.S. Medicaid pricing scheme, and continued U.S. manufacturing investment. In exchange, it will avoid pharmaceutical tariffs and future pricing mandates, though the specific terms remain confidential. Its planned $2 billion Georgia facility is projected to generate about $5 billion in U.S. economic impact and more than 330 permanent jobs. UCB says the plant complements rather than replaces global operations and points to roughly €300 million in previously announced Belgian projects, while offering no amount for future investment in Europe. The company did not clarify whether its commitments could mean higher prices for new medicines in European markets. The impact will become clearer when UCB next seeks European payer coverage for a new medicine.

Drug pricing Pharmaceutical manufacturing U.S.-EU economic relations Investment in biotechnology United States Belgium European Union White House U.S. Department of Health and Human Services U.S. Department of Commerce State of Georgia Rowen Foundation
Style rédactionnelInformatif

Mostly factual reporting, with some framing around the unanswered question of how the deal may affect European medicine prices.

AstraZeneca Belgium chief warns Europe’s drug access problem is undermining clinical research

Rapporteur 10 sept. 2026 English

Angela Thompson, AstraZeneca’s Belgium and Luxembourg president, says the company’s clinical-trial investment in Belgium has fallen by about 20% since 2024, citing slow European trial approvals and limited reimbursement of medicines. She argues that low access to approved medicines makes Belgium less attractive for trials, putting jobs, early patient access, and future investment at risk. Thompson urges governments to treat healthcare spending as a long-term economic investment and says stronger patent protection and reliable reimbursement are both needed to support pharmaceutical research. She also criticizes proposed eligibility rules for extending supplementary protection certificates as too restrictive, and warns that companies may direct investment elsewhere if Europe’s policy environment does not improve.

Pharmaceutical Industry Clinical Trials Medicine Reimbursement Healthcare Investment Drug Access Belgium Europe United States European Medicines Agency European Union China Angela Thompson
Style rédactionnelÉquilibré

Interview presents factual context alongside AstraZeneca’s executive arguing for increased healthcare investment, reimbursement, and stronger medicine protections.

New Alzheimer's drugs: what the next treatment wave could mean for patients

Rapporteur 9 sept. 2026 English

Disease-modifying Alzheimer's drugs have begun reaching European patients, but treatment depends on early, biomarker-confirmed diagnosis and access remains uneven; in the Czech Republic, initial patients must pay out of pocket. EU-approved lecanemab and donanemab require infusions and MRI monitoring because of the risk of brain swelling or bleeding. Research is expanding beyond amyloid toward tau, inflammation and immune targets, while newer delivery methods such as injectable lecanemab and trontinemab may reduce treatment burdens. A US-cleared p-tau217 blood test could make diagnosis easier, and researchers are also testing lifestyle-based care and prevention in people without symptoms.

Alzheimer's disease Alzheimer's drug development Early diagnosis Biomarker testing Access to treatment Czech Republic European Union United States European Commission Czech Brain Aging Study Mayo Clinic Study of Aging Katerina Sheardova
Style rédactionnelInformatif

Primarily factual reporting, with limited evaluative framing and attributed opinions from researchers.

Europe Has Plans for Cancer and Heart Disease—Lung Health Is Still Waiting

Rapporteur 8 sept. 2026 English

The European Union has dedicated plans for cancer and cardiovascular disease but no comprehensive lung-health strategy, despite the substantial burden of COPD and asthma. Patient and clinician groups are urging the EU to consolidate fragmented initiatives into a European Lung Health Plan, backed by coordinated prevention, earlier diagnosis, and long-term disease management. The article argues that better respiratory care could reduce avoidable hospital admissions and costs, strengthen strained health systems, improve patient outcomes, and lower healthcare emissions. It identifies the EU’s next long-term budget, beginning in 2028, as a key opportunity to fund coordinated action.

Respiratory Health Chronic Obstructive Pulmonary Disease Asthma European Union Health Policy Healthcare Sustainability Climate Change and Health European Union United Kingdom European Lung Health Group MEP Lung Health Group World Health Organization Organisation for Economic Co-operation and Development
Style rédactionnelInterprétatif

Advocates for a European lung-health plan, using evidence and persuasive language to argue for coordinated policy action.

Contexte politiqueCentre

Policy advocacy focused on public health, prevention, and healthcare sustainability rather than a partisan political position.

Locked Out of EU Science, Hungary Falls Behind on Alzheimer’s

Rapporteur 2 sept. 2026 English

Hungary’s exclusion from EU research programmes has disrupted university collaboration and is worsening the country’s ability to keep pace with advances in Alzheimer’s diagnosis and treatment. Although a late-May 2026 agreement began restoring some frozen funds, Horizon Europe access remains blocked while changes to university trusts are pending. A survey found substantial effects on early-career researchers, including plans to seek work abroad and greater difficulty maintaining international partnerships. Hungary also lacks a national dementia plan and adequate diagnostic infrastructure: only about 1% of an estimated 250,000 people with dementia have a biological diagnosis, limiting access to treatments intended for early Alzheimer’s. Andras Horvath calls for national testing standards, a dementia research fund and registry, a coordinated diagnostic pathway, and—above all—Hungary’s reintegration into European research programmes.

Alzheimer’s Disease Dementia Research EU Research Funding Healthcare in Hungary Medical Diagnosis Hungary European Union Budapest European Commission Horizon Europe Erasmus+ Court of Justice of the European Union
Style rédactionnelÉquilibré

Primarily reported information and attributed expert views, with some evaluative framing about Hungary’s research and diagnostic gaps.

The Biosimilar Void: Why Europe’s Next Decade of Drug Savings Is Not Guaranteed

Rapporteur 25 août 2026 English

Europe faces a projected shortfall in biosimilar competition as many biologic medicines lose exclusivity over the next decade. IQVIA estimates that missing development pipelines could forgo at least €15 billion in savings, with losses potentially much higher. The article attributes weak manufacturer participation to aggressive price erosion, single-winner tenders, international reference pricing, and additional cost-recovery measures. It argues that multi-winner procurement, incentives for prescribing and switching, and recognition of quality and supply reliability could sustain competition. Proposed opportunities include streamlined European Medicines Agency guidelines and a revision of EU procurement rules; policy choices will determine whether the next wave of patent expiries brings continued savings and access.

Biosimilars European Healthcare Drug Pricing and Procurement Medicine Access Pharmaceutical Market Competition Europe European Union Norway Medicines for Europe European Medicines Agency Adam Levysohn Samsung Bioepis
Style rédactionnelInterprétatif

Primarily evidence-led analysis, but it advances a clear policy argument for pro-competition procurement and sustainable market incentives.

Contexte politiqueCentre

Focuses on pharmaceutical procurement and healthcare policy, advocating competition and sustainability without a broader partisan position.

Belgium's medicine price cuts risk its own innovation, economist warns

Rapporteur 25 août 2026 English

Economist Walter Van Dyck argues that Belgium's aggressive medicine price reductions and delayed reimbursement may protect budgets in the short term but risk weakening pharmaceutical innovation and slowing patient access. With Paola Argiolas, he proposes reforming the clawback so overspending is attributed and balanced across years, preserving a price gap between branded and generic medicines and directing savings to innovation, paying for new medicines early with later price settlements, and creating a European fund for costly advanced therapies. He also warns that US Most-Favoured-Nation pricing could push European prices upward and delay access, while noting that joint European purchasing can reduce costs but pricing remains a national responsibility.

Pharmaceutical Pricing Medicine Access and Reimbursement Pharmaceutical Innovation European Health Policy Belgium European Union United States Belgian government European Commission Beneluxa Vlerick Business School Walter Van Dyck
Style rédactionnelInterprétatif

Interview-led argument advances policy recommendations and critiques Belgium's pricing approach, while including factual context.

Contexte politiqueCentre

Policy-focused discussion of pharmaceutical pricing and health-system design; it does not clearly align with a partisan ideology.

Voir les 13 réalisations avec un compte gratuit

Recruter Message
×

Inscrivez-vous pour envoyer un message à Nicole

Vous avez déjà un compte ? Se connecter
Vous cherchez du travail ? S'inscrire en tant que journaliste
Vérifiez votre e-mail pour finaliser l'inscription
Nous venons d'envoyer un e-mail à . Veuillez consulter votre boîte de réception et cliquer sur le lien pour vérifier votre adresse e-mail et finaliser votre inscription. Si vous ne voyez pas l'e-mail, pensez à vérifier votre dossier spam ou courrier indésirable.
Vous n'avez pas reçu l'e-mail ?

Inscrivez-vous pour débloquer les profils

Vous avez déjà un compte ? Se connecter
Vous cherchez du travail ? S'inscrire en tant que journaliste
Vérifiez votre e-mail pour finaliser l'inscription
Nous venons d'envoyer un e-mail à . Veuillez consulter votre boîte de réception et cliquer sur le lien pour vérifier votre adresse e-mail et finaliser votre inscription. Si vous ne voyez pas l'e-mail, pensez à vérifier votre dossier spam ou courrier indésirable.
Vous n'avez pas reçu l'e-mail ?